Specialty Medications: What Brokers Need to Know About Risk and Reinvestment

Specialty medications are often discussed in clinical terms. Breakthrough therapies. Complex conditions. Life-changing outcomes. 

For brokers, however, specialty drugs represent something else entirely. They are one of the largest and least predictable sources of financial risk in employer health plans. 

Understanding that risk and knowing how to reframe it is quickly becoming a defining skill for effective advisors. 

Why Specialty Medications Change the Equation 

Specialty drugs account for a disproportionate share of pharmacy spend, frequently driven by a small number of claimants. A single therapy can carry an annual cost that rivals or exceeds the total spend of dozens of traditional prescriptions combined. 

For employers, this creates volatility. For brokers, it creates responsibility. 

Specialty is no longer an edge case. It is a core component of pharmacy strategy.   

Where the Risk Actually Lives 

The financial risk of specialty medications is not limited to drug price alone. It is embedded throughout the system. 

High-Cost Claim Concentration  

Most specialty spending is driven by a very small population. Without visibility into emerging therapies and claimant trajectories, employers are often caught off guard when costs spike mid-year. 

Sourcing and Distribution Decisions 

Where and how specialty medications are sourced can materially affect cost. Limited network arrangements, exclusive specialty pharmacies, and opaque acquisition pricing can all inflate spend. 

Incentive-Driven Formularies 

Formulary placement is frequently influenced by rebate economics rather than lowest net cost. That dynamic can push higher-priced therapies to the forefront, increasing financial exposure. 

Limited Intervention Timing 

By the time many employers become aware of specialty costs, the prescription has already been filled and the financial impact locked in. 

Why Brokers Can’t Afford to Stay Hands-Off 

Historically, many brokers have deferred specialty strategy to PBMs and specialty pharmacies, trusting that clinical expertise equates to financial alignment. 

That assumption is increasingly risky. 

Employers now expect brokers to: 

• Anticipate risk, not just respond to it. 
• Explain why specialty costs rise. 
• Identify where oversight is lacking. 
• Help evaluate whether current strategies truly serve the plan. 

Avoiding specialty conversations does not reduce complexity. It shifts accountability. 

Reinvestment Starts with Oversight 

Managing specialty risk is not about denying care or restricting access. It is about ensuring that dollars are spent intentionally and aligned with plan goals. 

Reinvestment opportunities often emerge when employers: 

• Evaluate alternative sourcing strategies where appropriate. 
• Identify opportunities to intervene earlier in the treatment journey. 
• Reduce waste created by misaligned incentives. 
• Reallocate dollars toward benefits that support workforce needs. 

When specialty spend is managed proactively, financial impact can be redirected rather than simply absorbed.

How Brokers Add Strategic Value 

Brokers who entice specialty medications do not need to become clinical experts. They need to become strategic translators. 

That means: 

• Framing specialty drugs as a financial and governance issue. 
• Helping clients understand trade-offs and options. 
• Asking vendors to justify sourcing and formulary decisions. 
• Bringing specialty discussions into planning conversations, not just renewals. 

This approach strengthens broker credibility and deepens client trust. 

The Opportunity Ahead 

Specialty medications will continue to reshape employer health plans. Costs will rise. Therapies will evolve. Complexity will increase. 

Brokers who understand the risk and help clients reinvest wisely will stand apart from those who simply report on utilization after the fact. 

In specialty pharmacy, insight is no longer optional. It is the difference between reacting to cost and managing it.